Tandem Diabetes Care: Citigroup Raises PT to $11, Maintains Neutral Rating

Tandem Diabetes Care: Citigroup Raises PT to $11, Maintains Neutral Rating

Citigroup has recently raised its price target for Tandem Diabetes Care (TNDM) to $11, while maintaining a neutral rating on the stock. This move comes amidst a period of significant volatility and technical indicators suggesting a potential upward trend in the stock price.

On August 14, 2025, Tandem Diabetes Care's 15-minute chart displayed a RSI Oversold reading and a KDJ Golden Cross, indicating a potential shift in momentum towards an upward trend [1]. The RSI (Relative Strength Index) Oversold reading suggests that the stock price has fallen below its average price, signaling a potential buying opportunity. The KDJ Golden Cross, which shows that the stock price has crossed above its moving average, further reinforces the possibility of a price increase.

Despite these technical indicators, the company's recent stock price decline and the triggering of these indicators suggest a potential upward trend, investors should remain vigilant and stay informed of further developments and analyst opinions as they navigate the current stock landscape.

In addition to the recent technical indicators, Tandem Diabetes Care's strong product pipeline and strategic R&D focus on closed-loop systems and automated insulin delivery (AID) technology position it as a high-conviction growth investment [1]. The company's innovative products, such as the t:slim X2 insulin pump and the Mobi pump, set it apart from competitors.

However, the company's ability to navigate potential risks associated with its expansion into the pharmacy channel and the impact of CMS proposals on its business will be crucial in determining its long-term success.

The stock has experienced significant insider buying activity, with CFO Leigh Vosseller and CEO John F. Sheridan acquiring additional shares in the company [2]. The insider purchases suggest confidence in the company's future prospects, despite recent analyst downgrades and price target reductions.

Analysts have provided a mixed outlook on Tandem Diabetes Care, with some upgrading the stock while others have downgraded it. Royal Bank Of Canada, Wells Fargo & Company, and Canaccord Genuity Group have all issued positive ratings and price targets on the stock, while Citigroup and Piper Sandler have maintained a neutral rating with lower price targets [2].

In conclusion, while Citigroup's price target increase suggests a potential upward trend for Tandem Diabetes Care, investors should remain cautious and continue to monitor the company's performance and analyst opinions.

References:
[1] https://www.ainvest.com/news/tandem-diabetes-care-15min-chart-shows-rsi-oversold-kdj-golden-cross-signals-2508/
[2] https://www.marketbeat.com/instant-alerts/tandem-diabetes-care-nasdaqtndm-shares-gap-up-following-insider-buying-activity-2025-08-12/